• Je něco špatně v tomto záznamu ?

Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines

W. Islam, J. Fang, T. Imamura, T. Etrych, V. Subr, K. Ulbrich, H. Maeda,

. 2018 ; 17 (12) : 2643-2653. [pub] 20180919

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035012

Grantová podpora
NV16-28594A MZ0 CEP - Centrální evidence projektů

Enhanced permeability and retention (EPR) effect-based nanomedicine is a promising strategy for successful anticancer therapy. The EPR effect is based on tumor blood flow. Because advanced large tumors, as frequently seen in clinical settings, are heterogeneous, with regions of defective vasculature and blood flow, achieving the desired tumor drug delivery is difficult. Here, we utilized the EPR effect to increase drug delivery. To augment the EPR effect for improved therapeutic effects of nanomedicine, we exploited vascular mediators-the nitric oxide (NO) generators nitroglycerin (NG), hydroxyurea, and l-arginine. These compounds generate NO in tumors with relatively high selectivity. Using different nanosized drugs in our protocol significantly increased (1.5-2 times) delivery of nanomedicines to different solid tumor models, along with markedly improving (2-3-fold) the antitumor effects of these drugs. Also, in 7,12-dimethylbenz[a]anthracene-induced advanced end-stage breast cancer, often seen in clinical settings, 2 mg/kg polymer-conjugated pirarubicin (P-THP) with NG (0.2 mg/mouse) showed better effects than did 5 mg/kg P-THP, and 5 mg/kg P-THP used with NG resulted in cures or stable tumors (no tumor growth) for up to 120 days. Moreover, in a murine autochthonous azoxymethane/dextran sulfate sodium-induced colon cancer model, NO donors markedly improved the therapeutic effects of P-THP even after just one injection, results that were comparable with those achieved with three weekly P-THP treatments. These findings strongly suggest the potential usefulness of NO donors as EPR effect enhancers to improve the therapeutic efficacy of nanomedicines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035012
003      
CZ-PrNML
005      
20191017091044.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1535-7163.MCT-18-0696 $2 doi
035    __
$a (PubMed)30232144
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Islam, Waliul $u Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
245    10
$a Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines / $c W. Islam, J. Fang, T. Imamura, T. Etrych, V. Subr, K. Ulbrich, H. Maeda,
520    9_
$a Enhanced permeability and retention (EPR) effect-based nanomedicine is a promising strategy for successful anticancer therapy. The EPR effect is based on tumor blood flow. Because advanced large tumors, as frequently seen in clinical settings, are heterogeneous, with regions of defective vasculature and blood flow, achieving the desired tumor drug delivery is difficult. Here, we utilized the EPR effect to increase drug delivery. To augment the EPR effect for improved therapeutic effects of nanomedicine, we exploited vascular mediators-the nitric oxide (NO) generators nitroglycerin (NG), hydroxyurea, and l-arginine. These compounds generate NO in tumors with relatively high selectivity. Using different nanosized drugs in our protocol significantly increased (1.5-2 times) delivery of nanomedicines to different solid tumor models, along with markedly improving (2-3-fold) the antitumor effects of these drugs. Also, in 7,12-dimethylbenz[a]anthracene-induced advanced end-stage breast cancer, often seen in clinical settings, 2 mg/kg polymer-conjugated pirarubicin (P-THP) with NG (0.2 mg/mouse) showed better effects than did 5 mg/kg P-THP, and 5 mg/kg P-THP used with NG resulted in cures or stable tumors (no tumor growth) for up to 120 days. Moreover, in a murine autochthonous azoxymethane/dextran sulfate sodium-induced colon cancer model, NO donors markedly improved the therapeutic effects of P-THP even after just one injection, results that were comparable with those achieved with three weekly P-THP treatments. These findings strongly suggest the potential usefulness of NO donors as EPR effect enhancers to improve the therapeutic efficacy of nanomedicines.
650    _2
$a zvířata $7 D000818
650    _2
$a antitumorózní látky $x farmakologie $7 D000970
650    _2
$a arginin $x farmakologie $7 D001120
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a doxorubicin $x analogy a deriváty $x farmakologie $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hydroxymočovina $x farmakologie $7 D006918
650    _2
$a makromolekulární látky $x farmakologie $7 D046911
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    12
$a nanomedicína $7 D050997
650    _2
$a nanočástice $x chemie $7 D053758
650    _2
$a nádory $x krevní zásobení $x patologie $7 D009369
650    _2
$a oxid dusnatý $x biosyntéza $7 D009569
650    _2
$a donory oxidu dusnatého $x farmakologie $7 D020030
650    _2
$a nitroglycerin $x farmakologie $7 D005996
650    _2
$a permeabilita $7 D010539
650    _2
$a potkani Sprague-Dawley $7 D017207
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Fang, Jun $u Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
700    1_
$a Imamura, Takahisa $u Department of Molecular Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
700    1_
$a Etrych, Tomas $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Subr, Vladimir $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Ulbrich, Karel $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Maeda, Hiroshi $u Department of Microbiology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. maedabdr@sweet.ocn.ne.jp. BioDynamics Research Foundation, Kumamoto, Japan. Osaka University School of Medicine, Osaka, Japan.
773    0_
$w MED00006616 $t Molecular cancer therapeutics $x 1538-8514 $g Roč. 17, č. 12 (2018), s. 2643-2653
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30232144 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191017091512 $b ABA008
999    __
$a ok $b bmc $g 1451672 $s 1073562
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 17 $c 12 $d 2643-2653 $e 20180919 $i 1538-8514 $m Molecular cancer therapeutics $n Mol Cancer Ther $x MED00006616
GRA    __
$a NV16-28594A $p MZ0
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace